ClinicalTrials.gg
CompletedNCT02417961Updated May 23, 2018Results posted

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

A Phase 3 interventional study of Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 24 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-05-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
16th of 39
162 · median 128
Started
2015
with 1 other
Phase 3
20 of 39
1 open now
Registered
13th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 16th largest by enrollment, is one of 2 that started in 2015, is one of 20 in phase 3, and was the 13th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of the study is to assess functionality, performance, and reliability of an accessorized pre-filled syringe (APFS) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma.

03

Conditions studied

  • Asthma

Keywords

  • Asthma,
  • Bronchial Diseases,
  • Respiratory Tract Diseases,
  • Lung Diseases,
  • Obstructive Lung Diseases,
  • Benralizumab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines
  • Male and female patients aged 18 to 75 years of age at the time of Visit 1
  • Patient or caregiver must be willing and able to self-administer the IP ( product). Caregiver must be age of consent or older at the time of Visit 1, if applicable
  • Weight of ≥40 kg
  • Evidence of asthma as documented by either: Airway reversibility ( ≥12% and 200 ml) demonstrated at Visit 1 or 2 OR documented in the previous 12 months OR; Airflow variability in FEV1 ≥20% between pulmonary function testing documented in the 12 months prior to V2 OR; Airflow variability shown by >20% diurnal variability in peak flow observed in the patient's asthma action plan
  • Documented history of current treatment with ICS (Inhaled ) and LABA (Long-acting β2 agonists). The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. For ICS/LABA combination preparations, both the mid- and high-strength maintenance doses approved in the local country will meet this ICS criterion. Additional asthma controller medications (e.g., LTRAs (Leukotriene receptor antagonists), tiotropium, theophylline, oral corticosteroids) are allowed
  • Morning pre-bronchodilator (pre-BD) FEV1 of >50% predicted at Visit 1 or Visit 2
  • Not well controlled asthma as documented by either: An ACQ6 (Asthma Control Questionnaire 6) ≥1.5 OR; A peak flow of 60-80% predicted OR; An exacerbation, one or more, that required oral or systemic corticosteroids in the previous year OR; Any one of the following assessed by patient recall over the previous 2-4 weeks: Asthma symptoms >2 days/week; OR / Nighttime awakenings 1 or more/week; OR / Short acting beta2-agonist use for symptom control (not for prevention of exercise induced asthma) >2 days/week

Exclusion criteria

Exclusion criteria:

  • pulmonary disease other than asthma (eg, active lung infection, (Chronic obstructive pulmonary disease), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)
  • Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: Affect the safety of the patient throughout the study; Influence the findings of the studies or their interpretations; Impede the patient's ability to complete the entire duration of study
  • Known history of allergy or reaction to the IP formulation
  • History of anaphylaxis to any biologic therapy
  • History of Guillain-Barré syndrome
  • A helminth parasitic infection diagnosed within 24 weeks prior to the date is obtained that has not been treated with, or has failed to respond to standard of care therapy
  • Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening period
  • Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Benralizumab 30 mg

    Benralizumab administered subcutaneously every 4 weeks

    Biological: Benralizumab

Interventions

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously every 4 weeks

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home

    Number (%) of patients/caregivers who successfully administered benralizumab with an APFS at home among those who have been deemed by the Principal Investigator to be suitable for at-home administration and are still in the study. A successful administration is defined as an injection completed, an answer of "Yes" to all 5 questions in the Functioning Device Return Questionnaire for the GREGALE Clinical Study (Appendix to the Clinical Study Protocol), and adequately passed the visual inspection and function tests. The percentage is calculated among all patients/caregivers who had been deemed by the Principal Investigator to be suitable for at home administration and were still in the study at the time point.

    Time frame: Week 12, Week 16, and Weeks 12 and 16

  2. Number and Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional

    Number (%) of returned APFS used to administer benralizumab at home that have been evaluated as functional among all returned APFS used to administer benralizumab at home. A functional APFS is defined as an answer of "Yes" to all the questions in the visual inspection and function tests. The percentage is calculated among all returned APFS at the specified time point.

    Time frame: Week 12, Week 16

  3. Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)

    Number (%) of APFS used to administer benralizumab at home or in the clinic and have been reported as malfunctioning (Product Complaints). The percentage is calculated based on APFS dispensed and used for the specified time point.

    Time frame: Weeks 0, 4, 8, 12, 16, 0 to 8, 12 to 16, and 0 to 16

Secondary outcomes

  1. The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score

    The effect of benralizumab on asthma control metrics in terms of change from baseline in mean Asthma Control Questionnaire-6 (ACQ-6) score. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations, and rescue medication. Baseline is defined as the last non-missing observation prior to the first dose of study treatment. ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Smaller score indicates better controlled asthma.

    Time frame: Week 0 (baseline) and weeks 4, 8, 12, 16, 20

  2. The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab

    Mean PK Concentration at each visit

    Time frame: Baseline, Week 8, Week 20, and Week 28

  3. The Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels

    Blood eosinophil counts by timepoint

    Time frame: Baseline, Week 20, and Week 28

  4. The Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)

    Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive

    Time frame: Baseline until Week 28

07

Results

Posted Jun 12, 2017

Participant flow

Participant flow — Overall Study
MilestoneBenra 30 mg
Started116
Completed112
Not completed4
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home

Number (%) of patients/caregivers who successfully administered benralizumab with an APFS at home among those who have been deemed by the Principal Investigator to be suitable for at-home administration and are still in the study. A successful administration is defined as an injection completed, an answer of "Yes" to all 5 questions in the Functioning Device Return Questionnaire for the GREGALE Clinical Study (Appendix to the Clinical Study Protocol), and adequately passed the visual inspection and function tests. The percentage is calculated among all patients/caregivers who had been deemed by the Principal Investigator to be suitable for at home administration and were still in the study at the time point.

Time frame:
Week 12, Week 16, and Weeks 12 and 16
Reported as:
Count of participants · Participants
Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home
ParticipantsBenra 30 mg
Week 12112
Week 16108
Weeks 12 and 16106
Statistical analysis
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 98.2 · 95% CI 93.81 to 99.79Percentage of patients who successfully administered benralizumab with an APFS at home (Week 12)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 99.1 · 95% CI 94.99 to 99.98Percentage of patients who successfully administered benralizumab with an APFS at home (Week 16)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 93.0 · 95% CI 86.64 to 96.92Percentage of patients who successfully administered benralizumab with an APFS at home (Week 12 and 16)
PrimaryNumber and Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional

Number (%) of returned APFS used to administer benralizumab at home that have been evaluated as functional among all returned APFS used to administer benralizumab at home. A functional APFS is defined as an answer of "Yes" to all the questions in the visual inspection and function tests. The percentage is calculated among all returned APFS at the specified time point.

Time frame:
Week 12, Week 16
Reported as:
Count of participants · Participants
Number and Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional
ParticipantsBenra 30 mg
Week 12113
Week 16108
Statistical analysis
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 99.1 · 95% CI 95.21 to 99.98Percentage of patients returned functional APFS administered at home (Week 12)
  • Benra 30 mg · Clopper Pearson Exact CI · Percentage: 99.1 · 95% CI 94.99 to 99.98Percentage of patients returned functional APFS administered at home (Week 16)
PrimaryNumber and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)

Number (%) of APFS used to administer benralizumab at home or in the clinic and have been reported as malfunctioning (Product Complaints). The percentage is calculated based on APFS dispensed and used for the specified time point.

Time frame:
Weeks 0, 4, 8, 12, 16, 0 to 8, 12 to 16, and 0 to 16
Reported as:
Count of units · Accessorized Pre-filled Syringe
Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)
Accessorized Pre-filled SyringeBenra 30 mg
Week 00
Week 41
Week 80
Week 120
Week 160
Week 0 to 81
Week 12 to 160
Week 0 to 161
Statistical analysis
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.0 · 95% CI 0.00 to 3.13Percentage of mulfunctioning APFS used to administer benralizumab at home or clinic (Week 0)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.9 · 95% CI 0.02 to 4.67Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 4)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.0 · 95% CI 0.00 to 3.16Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 8)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.0 · 95% CI 0.00 to 3.13Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 12)
  • Benra 30 mg · Clopper-Pearson Exact CI · Percentage: 0 · 95% CI 0 to 3.33Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 16)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.3 · 95% CI 0.01 to 1.59Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 0 to 8)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.0 · 95% CI 0.00 to 1.63Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 12 to 16)
  • Benra 30 mg · Clopper-pearson Exact CI · Percentage: 0.2 · 95% CI 0.00 to 0.97Percentage of malfunctioning APFS used to administer benralizumab at home or clinic (Week 0 to 16)
SecondaryThe Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score

The effect of benralizumab on asthma control metrics in terms of change from baseline in mean Asthma Control Questionnaire-6 (ACQ-6) score. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations, and rescue medication. Baseline is defined as the last non-missing observation prior to the first dose of study treatment. ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Smaller score indicates better controlled asthma.

Time frame:
Week 0 (baseline) and weeks 4, 8, 12, 16, 20
Reported as:
Mean · Scores on a scale
The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score
Scores on a scaleBenra 30 mg
Week 4-0.53 ± 0.71
Week 8-0.54 ± 0.80
Week 12-0.72 ± 0.86
Week 16-0.82 ± 0.87
Week 20-0.73 ± 0.93
SecondaryThe Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab

Mean PK Concentration at each visit

Time frame:
Baseline, Week 8, Week 20, and Week 28
Reported as:
Geometric mean · ng/mL
The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab
ng/mLBenra 30 mg
BaselineNA ± NA
Week 81031.644 ± 53.547
Week 20802.197 ± 267.033
Week 2856.330 ± 499.728
SecondaryThe Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels

Blood eosinophil counts by timepoint

Time frame:
Baseline, Week 20, and Week 28
Reported as:
Mean · cells/ uL
The Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels
cells/ uLBenra 30 mg
Baseline362.2 ± 322.01
Week 2013.0 ± 56.33
Week 2847.1 ± 141.50
SecondaryThe Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)

Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive

Time frame:
Baseline until Week 28
Reported as:
Number · Participants
The Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)
ParticipantsBenra 30 mg
Positive at any visit17
Base- and Post-baseline Positive2
Only post-baseline positive13
Only baseline positive2
Persistently Positive14
Transiently Positive1

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg0/116 (0%)7/116 (6%)43/116 (37.1%)
Most frequent serious events
Most frequent serious events
EventBenra 30 mg
ColitisGastrointestinal disorders1/116
Large intestine polypGastrointestinal disorders1/116
Non-cardiac chest painGeneral disorders1/116
DiverticulitisInfections and infestations1/116
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/116
Spinal column stenosisMusculoskeletal and connective tissue disorders1/116
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/116
SyncopeNervous system disorders1/116
Most frequent other events
Most frequent other events
EventBenra 30 mg
NasopharyngitisInfections and infestations16/116
Upper respiratory tract infectionInfections and infestations13/116
SinusitisInfections and infestations6/116
HeadacheNervous system disorders6/116
Viral upper respiratory tract infectionInfections and infestations5/116
BronchitisInfections and infestations4/116
Back painMusculoskeletal and connective tissue disorders4/116

Baseline characteristics

Age, Continuous
Age, Continuous(years)Benra 30 mg
Mean47.6 ± 13.19
Sex: Female, Male
Sex: Female, Male(Participants)Benra 30 mg
Female64
Male52
08

Study locations

24 sites
  • Research Site
    Fountain Valley, California, United States
  • Research Site
    Walnut Creek, California, United States
  • Research Site
    Celebration, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Site
    Albany, Georgia, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Saint Louis, Missouri, United States
  • Research Site
    Bellevue, Nebraska, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Ajax, Ontario, Canada
  • Research Site
    Burlington, Ontario, Canada
  • Research Site
    Mississauga, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Pointe-Claire, Quebec, Canada
  • Research Site
    Quebec City, Quebec, Canada
  • Research Site
    St Charles Borromee, Quebec, Canada
  • Research Site
    Trois-Rivières, Quebec, Canada
  • Research Site
    Quebec, Canada
09

References and documents

Publications

  • Ferguson GT, Mansur AH, Jacobs JS, Hebert J, Clawson C, Tao W, Wu Y, Goldman M. Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. J Asthma Allergy. 2018 Apr 5;11:63-72. doi: 10.2147/JAA.S157762. eCollection 2018. PubMed 29670379 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Mar 2016, 10 months.

Results were first posted in Jun 2017, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 10 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2015
First posted
Apr 16, 2015
StartActual
Apr 27, 2015
Primary completionActual
Mar 14, 2016
CompletionActual
Mar 14, 2016
Results first posted
Jun 12, 2017
Last update
May 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02417961
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 16, 2015
Start date
Apr 27, 2015
Primary completion
Mar 14, 2016
Completion
Mar 14, 2016
Results posted
Jun 12, 2017
Last update
May 23, 2018

Study contacts

Gary T. Ferguson, MD, PC
principal investigator · Pulmonary Research Institute of Southeast Michigan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion